[CAR-T therapy for pediatric acute lymphoblastic leukemia]

Area of Science:

• Pediatric Hematology Oncology
• Immunotherapy
• Leukemia Research

Context:

• Significant improvements in pediatric B-cell acute lymphoblastic leukemia (B-ALL) survival rates over recent decades.
• Emergence of relapsed/refractory cases necessitates novel therapeutic strategies beyond conventional chemotherapy.
• Advancements include antibody-mediated immunotherapy and chimeric antigen receptor T-cell (CAR-T) therapy.

Purpose:

• To review the current landscape of B-ALL treatment, focusing on relapsed/refractory cases.
• To discuss the role and efficacy of tisagenlecleucel in managing high-risk B-ALL.
• To explore recent findings on risk factors for relapse after CAR-T therapy and the need for consolidative strategies.

Summary:

• Tisagenlecleucel demonstrates high complete remission rates in relapsed/refractory B-ALL, including chemotherapy-unresponsive, post-transplant relapse, and transplant-ineligible patients.
• Recent studies highlight critical risk factors associated with relapse post-tisagenlecleucel therapy.
• The necessity of consolidative therapy following tisagenlecleucel treatment is an active area of investigation.

Impact:

• Informs clinical decision-making for high-risk B-ALL patients undergoing novel immunotherapies.
• Guides future research directions in optimizing CAR-T cell therapy and post-treatment management.
• Contributes to improving long-term outcomes for pediatric, adolescent, and young adult B-ALL survivors.